2024 ISPE Annual Meeting

Share on:

Saturday, August 24 - Wednesday, August 28, 2024

Celebrating 40 Years of Advancing Pharmacoepidemiology

We are pleased to be a gold sponsor of ISPE 2024. Our team will also be attending, speaking, and presenting. Have a look at our schedule to see what you are interested in. Meet us at booth #801.

We are excited to recognize Andrea Margulis, Senior Director, Epidemiology, who is serving as Chair of this year's Scientific Program Commitee

Scroll down to see what we're bringing to ISPE and who will be attending.

Related Services

Pre-conference courses | All times are listed in Central European Summer Time (CEST)

Aug 25, 2:30 PM – 6:00 PM

Modern Pregnancy Pharmacoepidemiology: Methodological Challenges and Solutions in Study Design

Speaker: Andrea Margulis
Location: Conv Hall I D

Aug 25, 2:30 PM – 6:00 PM

Real-World Evidence (RWE) Generation for Rare Disease Drug Development and Orphan Drug Approvals

Speaker: Xabier Garcia de Albenez Martinez
Location: Room III

Conference Presentations & Moderators

Aug 26, 1:30 PM - 3:00 PM

Growing Old Gracefully

Moderator: Joan Forns Guzman

Location: Room II

Aug 26, 3:30 PM – 5:00 PM

Specification of time zero in causal inference studies using real-world data: challenges and solutions. Garcia de Albeniz Martinez X, Aguado J, Caniglia E, Hernanez-Diaz S, Maringe C, Sterne J.

Speaker: Xabier Garcia de Albeniz Martinez

Location: Conv Hall I C

Aug 27, 8:30 AM - 8:45 AM

Considerations for negative control outcome analyses in vaccine effectiveness studies: post-hoc analyses from an adult vaccine effectiveness study conducted within the FDA BEST initiative. Peetluk LS, Djibo DA, Layton JB, Deng J, Deshazo J, Richey MM, Ogilvie RP, Parambi RJ, Miller M, Song J, Tarazi W, Weatherby LB, Bell EJ, Anthony MS, McMahill-Walraven CN, Yang GW, Seeger JD, Amend KL.

Location: Conv Hall I C

Aug 27, 9:15 AM - 9:30 AM

Effectiveness over time of a complete primary series of the original, monovalent COVID-19 vaccines among adults aged 18-64 years in the United States. Layton JB, Peetluk LS, Lloyd PC, Jiao Y, Djibo DA, Deng J, Gruber JF, Ogilvie RP, Parambi R, Miller M, Song J, Weatherby LB, Bell EJ, Lo AC, Hervol JR, Wernecke M, Cho S, Wong H-L, Clarke TC, Bui CL, Stone A, Tarazi W, Deshazo J, Forshee RA, Anderson SA, Seeger JD, Amend KL, MaMahill-Walraven CN, Chillarige Y, Yang GW, Anthony MS, Shoaibi A.

Presenting Author: Bradley Layton

Location: Conv Hall I C

Aug 27, 1:00 PM - 1:15 PM

Events on day zero of follow-up: considerations for cohort studies of adverse events after COVID-19 diagnosis. Layton JB, Richey M, Lindaas A, Muthuri S, Lloyd PC, Gruber JF, Bui C, McKillop M, Kowarski L, Lyu H, Cheng A, Wan Z, Clarke TC, Kawai AT, Beers J, Forshee RA, Anderson SA, Burrell T, Chillarige Y, Anthony MS, Shoaibi A.

Presenting author: Bradley Layton

Location: Conv Hall I C

Aug 27, 1:00 PM - 2:30 PM

Pregnancy Potpourri

Co-Moderator: Elena Rivero-Ferrer

Location: Room XV

Aug 27, 4:15 PM – 5:45 PM

Building global consensus on definitions for drug safety studies in pregnancy to improve harmonized evaluation of real-world data. Broe A, Willis SK, Dareng E, Haviland M, van Gelder MMHJ, Nordeng HME, Wood ME, Sahin L, Margulis AV, Rivero-Ferrer E.

Speakers: Andrea V. Margulis

Location: Conv Hall I C

Aug 28, 8:30 AM - 10:00 AM

Lightning Session 3

Co-Moderator: Susan Perez-Gutthann

Location: Room lll

Aug 28, 8:45 AM - 9:00 AM

Impact of data source diversity on the distribution of key variables in pregnancy cohorts based on the ConcePTION pregnancy algorithm leveraging a random forest imputation model. Girardi A, Limoncella G, Hyeraci G, Roberto G, Bartolini C, Paoletti O, Messina D, Villalobos F, Bissacco C, Van den Burg J, Houben E, Santaca k, Lentile V, Ingrasciotta Y, Trifiro G, Hoxhaj V, Duran C, Riera-Arnau J, Garcia P, Martin-Perez M, Huerta-Alvarez C, Llorente-Garcia A, Sanchez-Saez F, Rodriguez-Bernal C, Lassalle R, Jove J, Bernard M, Thurin N, Jordan S, Thayer D, Evans H, Coldea A, Manfrini M, Van Gelder M, Hayati S, Schink T, Tari M, Pajouheshnia R, Afonso A, Noan-Laine M, Molgaard-Nielsen D, Cunnington M, Dodd C, Sturkenboom M, Nordeng H, Gini R.

Location: Room XV

Aug 28, 10:30 AM – 12:00 PM

Target trial emulation with real world evidence: regulatory grade pharmacoepidemiology in the SIGMA consortium. Haug U, Morales DR, Ehrenstein V, Esen BO, Didelez V, Schafer W, Reinbold J, Martinez D, Garcia de Albeniz X, Gini R, Ryan O, Young J.

Speakers: David Martinez, Xabier Garcia de Albeniz Martinez

Location: Conv Hall I C

Aug 28, 1:30 PM - 1:45 PM

Risk of neurologic or immune-mediated adverse events after COVID-19 diagnosis in the United States. Layton JB, Muthuri S, Lindaas A, Lloyd PC, Richey MM, Gruber JF, Clarke TC, Kowarski LS, McKillop M, Fisher S, Lyu H, Cheng A, Bui CL, Duenas PF, Chen Y, Forshee RA, Anderson SA, Beers JB, Burrell T, Chillarige Y, Anthony MS, Shoaibi A.

Presenting author: Bradley Layton

Location: Conv Hall I C

Aug 28, 2:45 PM - 3:00 PM

Risk of cardiovascular adverse events after COVID-19 diagnosis in the United States. Layton JB, Lindaas A, Muthuri S, Lloyd PC, Richey MM, Gruber JF, Clarke TC, Kowarski L, McKillop M, Fisher S, Lyu H, Cheng A, Bui C, Duenas PF, Chen Y, Beers JB, Forshee RA, Anderson SA, Burrell T, Chillarige Y, Anthony MS, Shoaibi A.

Presenting author: Bradley Layton

Location: Conv Hall I D

Aug 28, 3:15 PM – 4:45 PM

Should confounding control be based on subject-matter knowledge, or driven by the data? A debate. Arana A, Ehrenstein V, Guo Y, Ryan P.

Speaker: Alejandro Arana

Moderator: Andrea V. Margulis

Poster Session A - Monday, August 26 | 8:00 AM - 6:00 PM

12:15 PM - 1:15 PM

Describing diversity of real-world data sources: a new framework adapted from the DIVERSE initiative scoping review. Pajouheshnia R, Gini R, Gardarsdottir H, Bennett D, Li L, Gulea C, Wientzek-Fleischmann A, Bazelier M, Burcu M, Dodd C, Duran C, Kaplan S, Lanes S, Marinier K, Roberto G, Soman KV, Platt R, Setoguchi S, Hall G, Zhou X.

Spotlight Presentation

Presenting author: Romin Pajouheshnia

201

Drug utilisation of radium-223 under routine clinical practice (DIRECT) in Europe: a post-authorisation safety study. Weinrib R, Fortuny J, Martinez D, Kollhorst B, Haug U, Kousholt A, Ehrenstein V, Iversen P, Mortensen J, Bosch D, Kuppen M, Pisa F, Vassiley Z.

Presenting author: Rachel Weinrib

196

Use of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease: a multicountry report from the FOUNTAIN platform. Johannes CB, Ziemiecki R, Pladevall-Vila M, Kosvesdy CP, Ebert N, Thomsen RWW, Christiansen CF, Baak B, Cabaninas CR, Kashihara N, Yano Y, Kanegae H, Coleman CI, Okami S, Li u F, Layton JB, Vizcaya D, Oberprieler NG.

Presenting author: Bradley Layton

Poster Session B - Tuesday, August 27 | 8:00 AM - 6:00 PM

233

Algorithms to identify major congenital malformations in routinely collected healthcare databases: a systematic literature review. Jacobson MH, Sabido M, Afonso AS, Ajao A, Alghamdi EA, Andrade S, Bennett D, Kharat V, Kurzinger ML, Le Noan-Laine M, Molgaard-Nielsen D, Murray G, Rivero-Ferrer E, Lopez-Leon S.

264

Fetal and neonatal alloimmune thrombocytopenia: systematic literature review and challenges encountered. Riera-Guardia N, Margulis AV, Calingaert B, Fletcher MP, Patki K, Weiner E, Armstrong R, Rivero-Ferrer E.

Presenting author: Elena Rivero-Ferrer

219

Identification of migraine in electronic healthcare data sources: a headache for pharmacoepidemiologists – a systematic literature review. Forns J, Abellan A, Riera-Guardia N, Margulis AV, Rivero-Ferrer E.

Presenting author: Joan Forns

344

Interim results from the VAC4EU Post-Authorization Safety Study (PASS) among recipients of the Pfizer-BioNTech COVID-19 (Comirnaty®) vaccine in Europe. Weibel D, de Luise C, Cid Royo A, Ryan O, Vaz T, Aguado J, Marsal J, Garcia de Albeniz Martinez X, Weinrib R, Yefimenko N, Pala E, Poblador-Plou B, Gimeno-Miguel A, Santos-Mejias A, Marconi E, Barbieri E, Stona L, Lysen T, Roy D, Hyeraci G, Girardi A, Lupattelli A, Desalegn AA, Villalobos F, Bissacco CA, Kendrick K, Garg R, Rubino H, Sturkenboom MCJM, Arana A.

359

Safety of the Janssen COVID-19 vaccine (JCOVDEN) using VAC4EU European healthcare data sources: methods and results of the second study feasibility assessment. Ahmadizar F, Fortuny J, Royo AC, Plana E, Weinrib R, Garcia Esteban R, Boric K, Yefimenko N, Haugh M, Carreras JJ, Urchueguia-Fornes A, Correcher E, van den Berg JM, Lysen T, Villalobos F, Bissacco CA, Newbern EC, Willame C, Praet N, Sturkenboom MCJM.

Poster Session C - Wednesday, August 28 | 8:00 AM - 1:30 PM

CSPOT17

A post-authorization safety study of golimumab in ulcerative colitis using the Spanish ENEIDA registry (MK8259-042). Domenech E, Fortuny J, Martinez D, Tormos A, Huang Z, Hill D, Weinstein C, Esslinger S, Krumme A, Mines D, Gisbert J.

Presenting author: Joan Fortuny

347

Interim utilization results from a post-approval safety study of Pfizer-BioNTech monovalent COVID-19 vaccine in the United States. Mayer SE, Kawai A, Fuller CC, Agan AA, Rao S, Koram N, Calingaert B, Marshall J, Connolly JG, Moyneur E, Jamal-allial A, Brown J, Burk J, Chomistek A, Daniels K, Dea K, DeFor TA, Diessner B, Djibo DA, Ezzy S, Hawrusik R, Johannes CB, Kendrick K, Layton JB, Ma Q, Mai X, Mack M, Pawloski PA, Reynolds JS, Selvan M, Sharma V, Vetter J, McMahill-Walraven CN, Platt R, Gilsenan A.

131

A flexible open-source analytic pipeline for self-controlled analysis of real world data. Cid Royo A, Choi J, Plana E, Garcia Esteban R, Pajouheshnia R, Ryan O.

178